Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small interfering RNA |
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
N07XX14
|
| gptkbp:brand |
gptkb:Givlaari
|
| gptkbp:CASNumber |
1446321-46-5
|
| gptkbp:chemicalFormula |
C204H267F9N60O80P19S
|
| gptkbp:developer |
gptkb:Alnylam_Pharmaceuticals
|
| https://www.w3.org/2000/01/rdf-schema#label |
givosiran
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits aminolevulinic acid synthase 1 (ALAS1)
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
nausea
fatigue injection site reaction rash increased liver enzymes |
| gptkbp:usedFor |
gptkb:acute_hepatic_porphyria
|
| gptkbp:bfsParent |
gptkb:Givlaari
|
| gptkbp:bfsLayer |
7
|